AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARS Pharmaceuticals, Inc. Director's Dealing 2022

Nov 10, 2022

32159_dirs_2022-11-10_69dd9bbf-b639-40da-a0ec-a27445846f30.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2022-11-08

Reporting Person: RA CAPITAL MANAGEMENT, L.P. (Director)
Reporting Person: RA Capital Healthcare Fund LP (Director)
Reporting Person: RA Capital Nexus Fund II, L.P. (Director)
Reporting Person: Kolchinsky Peter (Director)
Reporting Person: Shah Rajeev M. (Director)

AI assistant

ARS Pharmaceuticals, Inc. — Director's Dealing 2022

32159_dirs_2022-11-10_69dd9bbf-b639-40da-a0ec-a27445846f30.zip

SEC Form 3 — Initial Statement of Beneficial Ownership

More from ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. Director's Dealing 2022